ADC Therapeutics SA reports results for the quarter ended in June - Earnings Summary

ADC Therapeutics SA

09/08/2022 15:25

* ADC Therapeutics SA  ADCT.N  reported a quarterly adjusted
loss
of 84 cents​​ per share for the quarter ended in June. The mean
expectation of six analysts for the quarter was for a loss of 91
cents per share.
    * Revenue rose 359.9% to $17.29 million from a year ago;
analysts
expected $20.51 million. 
    * ADC Therapeutics SA's reported EPS for the quarter was a
loss
of 84 cents​.
    * The mean earnings estimate of analysts had fallen by
about 0.1%
in the last three months.​ 
    * In the last 30 days there have been no negative revisions
of
earnings estimates 
    * ADC Therapeutics SA shares had risen by 1.3% this
quarter and
lost 60.1% so far this year.
    * The company reported a quarterly loss of $64.37 million.
    * Wall Street's median 12-month price target for ADC
Therapeutics
SA is $28.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data August 9
at 02:24 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2022      -0.91          -0.84          Beat
 Mar. 31 2022      -0.70          -0.22          Beat
 Dec. 31 2021      -0.86          -0.45          Beat
 Sep. 30 2021      -0.92          -0.93          Missed